JPWO2021262909A5 - - Google Patents

Info

Publication number
JPWO2021262909A5
JPWO2021262909A5 JP2022579691A JP2022579691A JPWO2021262909A5 JP WO2021262909 A5 JPWO2021262909 A5 JP WO2021262909A5 JP 2022579691 A JP2022579691 A JP 2022579691A JP 2022579691 A JP2022579691 A JP 2022579691A JP WO2021262909 A5 JPWO2021262909 A5 JP WO2021262909A5
Authority
JP
Japan
Application number
JP2022579691A
Other languages
Japanese (ja)
Other versions
JP2023531511A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/038780 external-priority patent/WO2021262909A2/en
Publication of JP2023531511A publication Critical patent/JP2023531511A/ja
Publication of JPWO2021262909A5 publication Critical patent/JPWO2021262909A5/ja
Pending legal-status Critical Current

Links

JP2022579691A 2020-06-23 2021-06-23 半減期が延長されたmRNA治療薬を含むLNP組成物 Pending JP2023531511A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063042822P 2020-06-23 2020-06-23
US63/042,822 2020-06-23
US202163165094P 2021-03-23 2021-03-23
US63/165,094 2021-03-23
US202163165469P 2021-03-24 2021-03-24
US63/165,469 2021-03-24
PCT/US2021/038780 WO2021262909A2 (en) 2020-06-23 2021-06-23 Lnp compositions comprising mrna therapeutics with extended half-life

Publications (2)

Publication Number Publication Date
JP2023531511A JP2023531511A (ja) 2023-07-24
JPWO2021262909A5 true JPWO2021262909A5 (de) 2024-07-01

Family

ID=77155849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579691A Pending JP2023531511A (ja) 2020-06-23 2021-06-23 半減期が延長されたmRNA治療薬を含むLNP組成物

Country Status (11)

Country Link
US (1) US20230242908A1 (de)
EP (1) EP4168556A2 (de)
JP (1) JP2023531511A (de)
KR (1) KR20230042005A (de)
CN (1) CN116194151A (de)
AU (1) AU2021297248A1 (de)
BR (1) BR112022025991A2 (de)
CA (1) CA3187261A1 (de)
IL (1) IL299196A (de)
MX (1) MX2022016550A (de)
WO (1) WO2021262909A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023183550A2 (en) * 2022-03-25 2023-09-28 Modernatx, Inc. Messenger ribonucleic acids with extended half-life
WO2023183909A2 (en) * 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
WO2023196399A1 (en) * 2022-04-06 2023-10-12 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
WO2023215498A2 (en) * 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8613481D0 (en) 1986-06-04 1986-07-09 Diatech Ltd Translation of mrna
US5723332A (en) 1993-11-26 1998-03-03 British Technology Group Limited Translational enhancer DNA
US5824497A (en) 1995-02-10 1998-10-20 Mcmaster University High efficiency translation of mRNA molecules
EP2428569B1 (de) 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mikrorna-moleküle
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
KR101541935B1 (ko) 2007-09-26 2015-08-05 인트렉손 코포레이션 합성 5'utr, 발현 벡터, 및 전이유전자 발현의 증가방법
CA3013503A1 (en) 2008-04-25 2009-10-29 Northwestern University Nanostructures suitable for sequestering cholesterol and other molecules
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
EA028860B1 (ru) 2009-06-10 2018-01-31 Арбутус Биофарма Корпорэйшн Улучшенная липидная композиция
AU2012207606B2 (en) 2011-01-11 2017-02-23 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
EP3434774A1 (de) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor-polynukleotide zur veränderung zellulärer phänotypen
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
EP3556353A3 (de) 2014-02-25 2020-03-18 Merck Sharp & Dohme Corp. Lipidnanopartikel-impfstoffadjuvanzien und antigenfreisetzungssysteme
WO2017066797A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
CA3024917A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Combinations of mrnas encoding immune modulating polypeptides and uses thereof
AU2019337637A1 (en) * 2018-09-13 2021-04-22 Modernatx, Inc. Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
JP2022500444A (ja) * 2018-09-14 2022-01-04 モダーナティエックス・インコーポレイテッドModernaTX, Inc. クリグラー−ナジャー症候群の治療のためのウリジン二リン酸グリコシルトランスフェラーゼ1ファミリー、ポリペプチドa1をコードするポリヌクレオチド
AU2021205337A1 (en) * 2020-01-10 2022-07-21 Modernatx, Inc. Methods of making tolerogenic dendritic cells
EP4096720A2 (de) * 2020-01-30 2022-12-07 ModernaTX, Inc. Für metabolische umprogrammierungspolypeptide codierende mrnas und deren verwendungen

Similar Documents

Publication Publication Date Title
JPWO2021262909A5 (de)
RU2022133733A3 (de)
RU2022119787A3 (de)
CN308403757S (de)
CN308404213S (de)
CN308666321S (de)
CN308662197S (de)
CN308403122S (de)
CN308662140S (de)
CN308627017S (de)
CN308403194S (de)
CN308610190S (de)
CN308600065S (de)
CN308403357S (de)
CN308403428S (de)
CN308403674S (de)
CN308501391S (de)
CN308494043S (de)
CN308488225S (de)
CN308438161S (de)
CN308407853S (de)
CN308407845S (de)
CN308403679S (de)
CN308404257S (de)
CN308407840S (de)